Insight into chromatin therapies for breast cancer could aid personalized medicine

February 7, 2018, Boston University School of Medicine

Most traditional chemotherapy for cancer has dangerous side effects, but new research is finding ways to develop 'targeted agents' that reduce the side effects and are better tailored to individual patient needs. While these innovations are exciting, a new study shows how certain cancer inhibitors need to be examined more carefully to better understand fine-grained effects and counter-effects, which could yield more effective and safer therapies.

Under the direction of Gerald V. Denis PhD, researchers at Boston University School of Medicine (BUSM) have long studied a family of three closely related proteins, called BET bromodomain proteins, comprised of BRD2, BRD3 and BRD4, which regulate gene expression. They were the first (in the 1990s) to show how these proteins function in human .

According to the researchers, new inhibitors of these proteins have generated a lot of excitement in cancer research because they may work well to block growth in diverse cancer types and seem to be less toxic than traditional chemotherapies. However, they also have known for a long time that the three proteins don't always work together.

"The field of the bromodomain proteins is fascinating" said the study's first author Guillaume Andrieu, PhD, post-doctoral research associate at BUSM. "A decade ago, the first drugs targeting the BET proteins were discovered. Since then, researchers have identified them as promising targets for cancer therapy, notably in lymphomas, but also in breast and prostate cancer. Yet, the contribution of each BET to cancer progression remains an obscure area as strategies aiming to block all of them at once have only been developed so far."

"In this study, we show that sometimes individual BET bromodomain proteins even oppose each other. Therefore, any of the pan-BET inhibitors that are currently available, which block all three, could have unexpected side effects or leave us working in the dark about their exact mechanisms of action," explained Denis, associate professor of medicine and pharmacology at BUSM and corresponding author of the study. "It has been established for several years now that BET proteins also exert protective roles in the body, notably by restricting viral infections including HIV," added Andrieu. "Therefore, it is urgent to develop new strategies to specifically target them to avoid deleterious effects."

Using human breast cancer cell lines that model estrogen receptor positive and triple negative tumor types, the researchers exposed them to a pan-BET inhibitor and compared what happened when they blocked expression of the three genes individually. They saw four patterns of expression important for 'epithelial-to-mesenchymal transition' (a program that tumor cells often activate to metastasize and to resist to treatments): one for the inhibitor and one for each of the individual genes, with surprisingly little overlap among them. "The results clearly show that the three proteins work independently and confirm our long stated concern that current pan-inhibitors are not sufficiently selective among the three. Based on this research, there are promising avenues to explore for more fine-tuned experiments and treatments," said Denis.

Denis believes this discovery should be seen in light of personalized medicine because some patients have high level expression of one or more BET proteins, some are intermediate and some are low. "Targeted drugs and patient profiling help oncologists understand which patients are most likely to benefit from tailored approaches, and which patients should be directed to alternate therapies. Personalized medicine is the most important innovation in cancer therapy since methotrexate was discovered in the 1950s as a chemotherapeutic drug for cancer, so it's important that the field move forward both quickly and carefully."

Cancer clinical trials using BET inhibitors are currently recruiting for leukemias, lymphoma, multiple myeloma, , lung cancer, glioblastoma and subtypes of breast cancer, including triple negative . "Our findings are urgently relevant to all of these trials, because the fundamental mechanisms we explored are shared across many cancer types," said Denis.

These findings appear in the journal Molecular Cancer Research.

Explore further: New proteins discovered that link obesity-driven diabetes to cancer

Related Stories

New proteins discovered that link obesity-driven diabetes to cancer

March 23, 2016
For the first time, researchers have determined how bromodomain (BRD) proteins work in type 2 diabetes, which may lead to a better understanding of the link between adult-onset diabetes and certain cancers.

Researchers identify protein required for breast cancer metastasis

November 15, 2016
Researchers have identified a new pathway and with it a protein, BRD4, necessary for breast cancer cells to spread.

Team targets tumor suppressor to treat 'triple-negative' breast cancer

February 5, 2018
A study by scientists at the University of Arizona Cancer Center and Cancer Research UK has found that the loss of a specific tumor suppressor in "triple-negative" breast cancer provides clues about potential new approaches ...

Discovery of new prostate cancer biomarkers could improve precision therapy

August 14, 2017
Mayo Clinic researchers have identified a new cause of treatment resistance in prostate cancer. Their discovery also suggests ways to improve prostate cancer therapy. The findings appear in Nature Medicine. In the publication, ...

Targeting breast cancer through precision medicine

January 9, 2018
University of Alberta researchers have discovered a mechanism that may make cancer cells more susceptible to treatment. The research team found that the protein RYBP prevents DNA repair in cancer cells, including breast cancer.

Anti-tumor immunity identified with new ovarian cancer treatment strategy

September 13, 2016
Few effective treatments have been approved to treat ovarian cancer, the deadliest of all cancers affecting the female reproductive system. Now, new research from The Wistar Institute demonstrates how a drug already in clinical ...

Recommended for you

Researchers identify a mechanism that fuels cancer cells' growth

November 14, 2018
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes ...

A new approach to detecting cancer earlier from blood tests: study

November 14, 2018
Cancer scientists led by principal investigator Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have combined "liquid biopsy", epigenetic alterations and machine learning to develop a blood test to detect and classify ...

New antibody breakthrough to lead the fight against cancer

November 14, 2018
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defence against the body's immune system.

Photoacoustic imaging may help doctors detect ovarian tumors earlier

November 14, 2018
Ovarian cancer claims the lives of more than 14,000 in the U.S. each year, ranking fifth among cancer deaths in women. A multidisciplinary team at Washington University in St. Louis has found an innovative way to use sound ...

Solving the mystery of NPM1 in acute myeloid leukemia

November 13, 2018
Although it has long been recognized that mutations of gene NPM1 play an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.